AbbVie Gets European Expanded Approval of Venclyxto
25 May 2021 - 11:03PM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Tuesday said the European Commission approved the
expanded use of its cancer drug Venclyxto in combination with a
hypomethylating agent for the treatment of adults with newly
diagnosed acute myeloid leukemia who are ineligible for intensive
chemotherapy.
The North Chicago, Ill., biopharmaceutical company said the
approval is based on a Phase 3 study in which patients who received
Venclyxto in combination with the hypomethylating agent azacitidine
showed statistically significantly greater median overall survival
than patients receiving azacitidine alone.
AbbVie and Roche Holding AG are jointly developing Venclyxto,
which is approved for indications in chronic lymphocytic leukemia
and acute myeloid leukemia. The drug is jointly marketed by AbbVie
and Roche's Genentech in the U.S., and by AbbVie alone outside the
U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 25, 2021 08:55 ET (12:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024